Clinical Immunology Unit, Immunology, Department, Hospital General Universitario, Gregorio Marañón, Departamento de Microbiología I, Universidad Complutense de Madrid, Spain.
Clin Exp Immunol. 2011 Apr;164(1):100–7. doi: 10.1111/j.1365-2249.2011.04320.x.
Recurrent respiratory tract infections (RRTIs) are common clinical conditions in individuals with alterations of the immune function. A prospective open pilot study in a cohort of patients with RRTIs has been performed to assess whether sublingual immunization with a polyvalent bacterial vaccine could exert an immunomodulatory effect on the antigen-specific immunological responses and have an impact on the clinical outcome. Seventeen patients with RRTIs were recruited. An oral polyvalent bacterial preparation (Bactek®) was administered to all patients daily for 6 months. Immunological assessment was performed at baseline and at the end of immunization. Immunological measurements included: T cell-specific proliferations of CD3+CD4+ and CD3+CD8+ to Bactek® antigens, total immunoglobulin levels, antibodies to pneumococcal polysaccharide and tetanus toxoid and B, T and natural killer (NK) cell subsets. There was a significant increase in the proliferative capacity of CD3+CD4+ T cells specific to Bactek® antigens at month 6 in comparison to baseline (P < 0·0001). A significant increase in total CD3+ T cells was also observed (P < 0·05). No significant differences were observed between baseline and month 6 in levels of total immunoglobulins, specific antibodies and B, T or NK cell subsets. A significant reduction in the patient's rate of RRTIs was observed compared with 1 year prior to initiation of therapy (P < 0·0001). The results demonstrate that long-term administration of a sublingual polyvalent bacterial preparation in patients with RRTIs exerts an immune stimulating effect on CD4+ T helper cell responses to bacterial antigens which could be associated with clinical benefit.
复发性呼吸道感染（RRTIs）是免疫功能改变个体的常见临床病症。对 RRTIs 患者进行了一项前瞻性、开放性的初步研究，以评估舌下免疫接种多价细菌疫苗是否对特定抗原的免疫反应具有免疫调节作用，并对临床结果产生影响。共招募了 17 例 RRTIs 患者。所有患者均每日接受口服多价细菌制剂（Bactek®）治疗，持续 6 个月。在基线和免疫接种结束时进行免疫评估。免疫测定包括：Bactek®抗原对 CD3+CD4+和 CD3+CD8+T 细胞的特异性增殖、总免疫球蛋白水平、肺炎球菌多糖和破伤风类毒素抗体以及 B、T 和自然杀伤（NK）细胞亚群。与基线相比，第 6 个月时 Bactek®抗原特异性 CD3+CD4+T 细胞的增殖能力显著增加（P<0·0001）。总 CD3+T 细胞也显著增加（P<0·05）。总免疫球蛋白、特异性抗体以及 B、T 或 NK 细胞亚群的水平在基线和第 6 个月之间无显著差异。与治疗前 1 年相比，患者 RRTIs 的发生率显著降低（P<0·0001）。结果表明，长期给予 RRTIs 患者舌下多价细菌制剂可刺激 CD4+T 辅助细胞对细菌抗原的免疫反应，这可能与临床获益相关。
